What is APIMEDS PHARMACEUTICALS US INC's earnings per share (EPS)?

APIMEDS PHARMACEUTICALS US INC (APUS) reported diluted earnings per share of -$0.55 for fiscal year 2025. This represents a -205.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

APIMEDS PHARMACEUTICALS US INC Financials

APUS

FY2025 annual

Revenue Not reported for FY2025

Net Income -$6.0M YoY not available

EPS (Diluted) -$0.55 -205.6% YoY

Free Cash Flow -$9.0M YoY not available

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

This page shows APIMEDS PHARMACEUTICALS US INC (APUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APUS FY2025 2026-08-26

The business is funded by capital inflows while overhead, not fixed-asset investment, drives its cash consumption.

From FY2023 to FY2025, equity rose from $32K to $153.3M, changing the balance-sheet cushion from thin to substantial. Debt-to-equity fell from 12.2x to 0.1x, so FY2025 losses occurred within a far less debt-heavy structure than in FY2023.

Operating cash flow of -$8.9M nearly matched free cash flow of -$9.0M in FY2025, indicating that cash use was not mainly a capital-spending cycle. With capital expenditures of only $57K, the funding need came overwhelmingly from day-to-day operations; financing cash flow of $20.6M supplied the offset.

SG&A was $10.3M versus $1.6M of R&D in FY2025, making overhead the dominant disclosed operating burden. The operating loss of -$11.9M was materially larger than the net loss of -$6.0M, meaning items below operating income reduced part of the reported deficit.

Financial Health Signals

Financial health score not available

APIMEDS PHARMACEUTICALS US INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/5

APIMEDS PHARMACEUTICALS US INC passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

APIMEDS PHARMACEUTICALS US INC reported a net loss of $6.0M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

APIMEDS PHARMACEUTICALS US INC reported an operating loss of $11.9M against $283K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$11.9M

APIMEDS PHARMACEUTICALS US INC's EBITDA was -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$6.0M

APIMEDS PHARMACEUTICALS US INC reported -$6.0M in net income in fiscal year 2025.

EPS (Diluted)

-$0.55

YoY-205.6%

APIMEDS PHARMACEUTICALS US INC earned -$0.55 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 205.6% from the prior year.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$9.0M

APIMEDS PHARMACEUTICALS US INC recorded an outflow of $9.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.

Cash & Debt

$1.6M

YoY+47270.6%

APIMEDS PHARMACEUTICALS US INC held $1.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

13M

YoY+53.5%

APIMEDS PHARMACEUTICALS US INC had 13M shares outstanding in fiscal year 2025. This represents an increase of 53.5% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-3.9%

APIMEDS PHARMACEUTICALS US INC's ROE was -3.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$1.6M

APIMEDS PHARMACEUTICALS US INC invested $1.6M in research and development in fiscal year 2025.

Capital Expenditures

$57K

APIMEDS PHARMACEUTICALS US INC invested $57K in capex in fiscal year 2025, funding long-term assets and infrastructure.

Share Buybacks

Not reported for fiscal year 2025.

APUS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APUS annual income statement

Metric	TTM	FY25	FY24	FY23
R&D Expenses	N/A	$1.6M	N/A	$99K
SG&A Expenses	N/A	$10.3M	N/A	$649K
Operating Income	N/A	-$11.9M	N/A	-$747K
Interest Expense	N/A	$283K	N/A	$38K
Net Income	N/A	-$6.0M	N/A	-$778K
EPS (Diluted)	—	-$0.55-205.6%	-$0.18-5.9%	-$0.17

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$960K+6.5%	$901K	N/A	$620K-4.9%	$652K	N/A	N/A	N/A
SG&A Expenses	$5.3M-52.9%	$11.3M	N/A	$1.2M-39.1%	$2.0M+452.2%	$364K	N/A	$300K
Operating Income	-$6.3M+48.5%	-$12.2M	N/A	-$1.8M+30.8%	-$2.7M-631.1%	-$364K	N/A	-$300K
Interest Expense	$3.2M+38337.5%	$8K	N/A	$6K+104.4%	$3K-99.6%	$851K	N/A	$33K
Net Income	-$20.2M+42.5%	-$35.1M	N/A	-$1.8M+33.1%	-$2.7M-561.6%	-$402K	N/A	-$333K
EPS (Diluted)	-$11.77	-$2.26	N/A	-$0.14	-$2.57	-$0.05	N/A	-$0.04

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

APUS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APUS annual balance sheet

Metric	FY25	FY24	FY23
Total Assets	$164.2M+1257338.4%	$13K-96.9%	$422K
Current Assets	$14.0M+106998.6%	$13K-96.9%	$422K
Cash & Equivalents	$1.6M+47270.6%	$3K-99.2%	$410K
Total Liabilities	$10.8M+690.3%	$1.4M+251.4%	$390K
Current Liabilities	$10.7M+945.2%	$1.0M+730.7%	$123K
Total Equity	$153.3M+11391.2%	-$1.4M-4361.6%	$32K
Retained Earnings	-$10.4M-136.6%	-$4.4M-46.3%	-$3.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$127.6M-9.6%	$141.2M-14.0%	$164.2M+1675.0%	$9.3M-12.3%	$10.5M+3957.9%	$260K+1890.5%	$13K	N/A
Current Assets	$10.7M-18.8%	$13.2M-5.9%	$14.0M+53.9%	$9.1M-12.2%	$10.3M+3882.1%	$260K+1890.5%	$13K	N/A
Cash & Equivalents	$278K-71.6%	$980K-40.2%	$1.6M-76.6%	$7.0M-20.0%	$8.7M+3388.1%	$250K+7148.4%	$3K-87.0%	$27K
Total Liabilities	$21.2M+44.0%	$14.7M+35.7%	$10.8M+894.7%	$1.1M+34.7%	$809K-60.0%	$2.0M+47.3%	$1.4M	N/A
Current Liabilities	$21.1M+44.5%	$14.6M+36.2%	$10.7M+882.8%	$1.1M+34.7%	$809K-54.3%	$1.8M+72.8%	$1.0M	N/A
Total Equity	$106.4M-15.9%	$126.5M-17.5%	$153.3M+1779.1%	$8.2M-16.2%	$9.7M+653.1%	-$1.8M-29.6%	-$1.4M-29.8%	-$1.0M
Retained Earnings	-$65.6M-44.4%	-$45.5M-337.3%	-$10.4M-12.5%	-$9.2M-23.9%	-$7.5M-55.5%	-$4.8M-9.2%	-$4.4M	N/A

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

APUS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APUS annual cash flow statement

Metric	TTM	FY25	FY24	FY23
Operating Cash Flow	-$13.3M	-$8.9M	N/A	-$628K
Capital Expenditures	$53K	$57K	N/A	N/A
Free Cash Flow	-$13.3M	-$9.0M	N/A	N/A
Investing Cash Flow	-$8.1M	-$10.1M	N/A	N/A
Financing Cash Flow	$12.9M	$20.6M	N/A	$1.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$5.7M-174.1%	-$2.1M+45.8%	-$3.8M-121.2%	-$1.7M+48.6%	-$3.4M-16446.5%	-$20K	N/A	-$187K
Capital Expenditures	$0-100.0%	$9K-56.2%	$21K-5.0%	$23K	N/A	N/A	N/A	N/A
Free Cash Flow	-$5.7M-172.8%	-$2.1M+45.9%	-$3.8M-119.6%	-$1.7M	N/A	N/A	N/A	N/A
Investing Cash Flow	$1.5M+205.7%	$491K+104.9%	-$10.0M-44374.0%	-$23K	N/A	N/A	N/A	N/A
Financing Cash Flow	$3.5M+276.7%	$920K-89.2%	$8.5M	$0-100.0%	$11.9M+4338.4%	$267K	N/A	$150K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

APUS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

APUS annual financial ratios

Metric	FY25	FY24	FY23
Return on Equity	-3.9%	N/A	-2440.3%
Return on Assets	-3.7%	N/A	-184.3%
Current Ratio	1.31+1.3x	0.01-3.4x	3.42
Debt-to-Equity	0.07	N/A	12.24

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-18.9%+8.8pp	-27.7%	N/A	-21.8%+5.5pp	-27.3%	N/A	N/A	N/A
Return on Assets	-15.8%+9.0pp	-24.8%	N/A	-19.3%+6.0pp	-25.2%+129.6pp	-154.8%	N/A	N/A
Current Ratio	0.51-0.4x	0.90-0.4x	1.31-7.0x	8.34-4.5x	12.79+12.6x	0.15+0.1x	0.01	N/A
Debt-to-Equity	0.20+0.1x	0.120.0x	0.07-0.1x	0.13+0.1x	0.08	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Aytu Biopharma Inc AYTU

$25.2M

Talphera Inc TLPH

$63.8M

Gelteq Limited GELS

$5.9M

Flora Growth Corp FLGC

$21.6M

Therapeuticsmd Inc TXMD

$26.4M

Where APIMEDS PHARMACEUTICALS US INC Ranks

Frequently Asked Questions

Is APIMEDS PHARMACEUTICALS US INC profitable?

No, APIMEDS PHARMACEUTICALS US INC (APUS) reported a net income of -$6.0M in fiscal year 2025.

What is APIMEDS PHARMACEUTICALS US INC's EBITDA?

APIMEDS PHARMACEUTICALS US INC (APUS) had EBITDA of -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is APIMEDS PHARMACEUTICALS US INC's return on equity (ROE)?

APIMEDS PHARMACEUTICALS US INC (APUS) has a return on equity of -3.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is APIMEDS PHARMACEUTICALS US INC's free cash flow?

APIMEDS PHARMACEUTICALS US INC (APUS) recorded an outflow of $9.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is APIMEDS PHARMACEUTICALS US INC's operating cash flow?

APIMEDS PHARMACEUTICALS US INC (APUS) recorded an outflow of $8.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are APIMEDS PHARMACEUTICALS US INC's total assets?

APIMEDS PHARMACEUTICALS US INC (APUS) had $164.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are APIMEDS PHARMACEUTICALS US INC's capital expenditures?

APIMEDS PHARMACEUTICALS US INC (APUS) invested $57K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does APIMEDS PHARMACEUTICALS US INC spend on research and development?

APIMEDS PHARMACEUTICALS US INC (APUS) invested $1.6M in research and development during fiscal year 2025.

How many shares does APIMEDS PHARMACEUTICALS US INC have outstanding?

APIMEDS PHARMACEUTICALS US INC (APUS) had 13M shares outstanding as of fiscal year 2025.

What is APIMEDS PHARMACEUTICALS US INC's current ratio?

APIMEDS PHARMACEUTICALS US INC (APUS) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.

What is APIMEDS PHARMACEUTICALS US INC's debt-to-equity ratio?

APIMEDS PHARMACEUTICALS US INC (APUS) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is APIMEDS PHARMACEUTICALS US INC's return on assets (ROA)?

APIMEDS PHARMACEUTICALS US INC (APUS) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does APIMEDS PHARMACEUTICALS US INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, APIMEDS PHARMACEUTICALS US INC (APUS) held $3.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.9M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is APIMEDS PHARMACEUTICALS US INC's Piotroski F-Score?

APIMEDS PHARMACEUTICALS US INC (APUS) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are APIMEDS PHARMACEUTICALS US INC's earnings high quality?

APIMEDS PHARMACEUTICALS US INC (APUS) reported a net loss of $6.0M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can APIMEDS PHARMACEUTICALS US INC cover its interest payments?

APIMEDS PHARMACEUTICALS US INC (APUS) reported an operating loss of $11.9M against $283K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.